Showing posts with label alzheimer's and memory. Show all posts
Showing posts with label alzheimer's and memory. Show all posts

Thursday, July 17, 2014

Discovery of new drug targets for memory impairment in Alzheimer's disease

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle

Medical Xpress
 

Research team in Korea has discovered that reactive astrocytes, which have been commonly observed in Alzheimer's patients, aberrantly and abundantly produce the chief inhibitory neurotransmitter GABA and release it through the Best1 channel. The released GABA strongly inhibits neighboring neurons to cause impairment in synaptic transmission, plasticity and memory. This discovery will open a new chapter in the development of new drugs for treating such diseases.

 Alzheimer's disease, which is the most common cause of dementia, is fatal and currently, there is no cure. In Alzheimer's disease, brain cells are damaged and destroyed, leading to devastating memory loss. It is reported that 1 in 8 Americans aged 65 or over have Alzheimer's disease. In 2011, 7,600 elderly people with dementia lost their way back home and became homeless in Korea. However, to date, there has been no clear understanding of the mechanisms underlying dementia in Alzheimer's disease. So far, neuronal death is the only proposed mechanism available in scientific literature.

The research team led by Dr. C. Justin Lee at Korea Institute of Science and Technology (KIST) and Dr. Daesoo Kim(KAIST) discovered that reactive astrocytes in the brains of Alzheimer's disease model mice produce the inhibitory transmitter GABA by the enzyme Monoamine oxidase B (MAO-B) and release GABA through the Bestrophin-1 channel to suppress normal information flow during . Based on this discovery, the team was able to reduce the production and release of GABA by inhibiting MAO-B or Bestrophin-1, and successfully ameliorate impairments in , synaptic transmission and memory in Alzheimer's disease model mice.

In the behavioral test, the team used the fact that mice tend to prefer dark places. If a mouse experiences an electric shock in a dark place, it will remember this event and avoid dark places from then on. However, a mouse with modeled Alzheimer's disease cannot remember if such shock is related to dark places and keeps going back to dark places. The team demonstrated that treating these mice with a MAO-B inhibitor fully recovered the mice's memory. The selegiline is currently used in Parkinson's disease as an adjunct therapy and considered as a one of best promising medicine for MAO-B inhibitor. But it has been previously shown to be less effective in Alzheimer's

 

Wednesday, January 11, 2012

Why do old people lose their memory

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

The stereotype of the old forgetful person whose memory often fails him is widely held, but the reason for its appearance was never really pinpointed. Much like gray hair and wrinkles, it was just thought to be part of growing old.

Now new research from Adam M. Brickman, PhD, of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University Medical Center in New York, shows that silent strokes may be the cause. Essentially small dead spots in the brain are found in one out of four elderly people.

Brickman's study is published in the January 3rd issue of Neurology®, the medical journal of the American Academy of Neurology and he states :


"The new aspect of this study of memory loss in the elderly is that it examines silent strokes and hippocampal shrinkage simultaneously."


His study was conducted with over 650 people aged 65 and older. They were free from dementia and were given MRI brain scans. They also took tests to measure their memory, language, speed at processing information and visual perception. Of the 658 people, 174 were identified as having had silent strokes.

Those 174 scored worse on memory tests, regardless of how large their hippocampus was. (The hippocampus is where the brain stores its memories.)

Brickman says that :


"Given that conditions like Alzheimer's disease are defined mainly by memory problems, our results may lead to further insight into what causes symptoms and the development of new interventions for prevention. Since silent strokes and the volume of the hippocampus appeared to be associated with memory loss separately in our study, our results also support stroke prevention as a means for staving off memory problems."


It's not known exactly why or how Alzheimer's destroys the brain's memory, but research has started to show accumulations of proteins called called amyloid plaques, among brain cells. Larger tangled protein strands then start to appear inside the cells. However, treatments to remove the proteins have not been particularly successful in improving memory loss.

Brickman's research points the investigation in a new direction, and focuses more on the vascular system. While circulation and loss of brain function from minute strokes may not be the whole solution its certainly an important part of it, as Brickman concludes :


"What our study suggests is, even when we account for the decline in memory attributed to hippocampal shrinkage or degeneration, that strokes ... play an additional role in the memory decline," Brickman says. He is the Herbert Irving assistant professor of neuropsychology at Columbia University College of Physicians and Surgeons.


Written by Rupert Shepherd
Copyright: Medical News Today
Not to be reproduced without permission of Medical News

Thursday, January 14, 2010

Nutritional drink, imaging show promise for Alzheimer's (part 2)

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting Corrier-journal.comactivities

Here is a dementia music activity



(CNN)

Scanning for the earliest signs

While the Souvenaid study focused on the loss of synapses as the mechanism behind Alzheimer's symptoms, an Italian group is working on identifying a different marker of the condition.

In a study published in the journal Neurology, researchers showed that a kind of MRI called diffusion tensor imaging may pick up signs of Alzheimer's in healthy elderly individuals.

Lead author Dr. Giovanni Carlesimo, of Tor Vergata University and the Santa Lucia Foundation in Rome, Italy, said the findings are preliminary but could be useful for future drug therapies to target the specific brain changes shown on the scan.

Researchers looked at the hippocampus, the brain structure associated with memory. They found that the mean diffusivity of the hippocampus -- a measure of how water is distributed within the tissues -- was correlated with how well participants performed on tests of verbal and visual-spatial memory.

The mean diffusivity in the hippocampus, as reflected in this brain scan, could represent some of the earliest structural changes that occur in the early stages of Alzheimer's, researchers say.

The research was done on 76 healthy people ages 20 to 80. The effect was most pronounced in the over-50-year-olds, the scientists reported.

The study is an important demonstration that MRI can be used to understand age-associated changes in the brain, said Adam Brickman, assistant professor of neuropsychology at Columbia University Medical Center.

But Brickman cautioned that this does not mean everyone should request this test.

"This might be something that will be useful down the road, but it's not diagnostic right now," he said.

Wednesday, January 13, 2010

Nutritional drink, imaging show promise for Alzheimer's

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting Corrier-journal.comactivities

Here is a dementia music activity



(CNN) -- Doctors are already good at diagnosing Alzheimer's disease in a patient with obvious symptoms, which include memory loss, vision problems and confusion. But the cutting-edge research is looking for the brain mechanisms of the condition at its earliest stages, maximizing the potential for intervention.

Two studies published this week that may help pave the way for better treatments for people with Alzheimer's, which affects as many as 5.3 million Americans, according to the Alzheimer's Association. One is a drink that you may one day be able to pick up at the pharmacy; the other is a detection method.

Drink to your health?

One of the features of a brain with Alzheimer's disease is the loss of synapses, which are junctions between two neurons or between a neuron and a muscle. Research suggests some connection between low numbers of synapses in a person's brain and Alzheimer's symptoms such as memory impairment and language deterioration.

Scientists have developed a drink called Souvenaid that is a "medical food," meaning it's taken under the guidance of a physician to manage a specific condition. The drink has three components -- uridine, choline, and the omega-3 fatty acid DHA -- that, working together, help restore synapses, said Dr. Richard Wurtman, professor at the Massachusetts Institute of Technology and co-author of the study. Uridine is a molecule used in the genetic coding for RNA, choline is in the vitamin B family, and DHA is found in certain fish and fish oils.

These nutrients are already found in the human body and have been shown to be safe, he said. But taking a supplement of any one of them will not have the same beneficial effect, he said. Together in the right proportions, the cocktail increases the production of fatty constituents and proteins needed for synapses.

The study looked at 225 patients who had mild Alzheimer's, according to an examination. Some took Souvenaid, and the control group participants received a non-medical drink, once a day for 12 weeks.

They found that patients showed significant improvement in the delayed verbal recall task, in which participants were asked to remember what they had been told earlier. The idea is that the formation of synapses delays the symptoms of Alzheimer's, but it is not a cure, experts said.

"There was a clear difference. The difference was greatest in people with very mild but quite real Alzheimer's," he said.

The product may be commercialized as early as next year, Nigel Hughes, general manager of Nutricia America. Nutricia is a unit of the international food giant Danone (Dannon in the United States), for which Wurtman is also a consultant.

There are other clinical studies of Souvenaid going on of 500 participants each, and the company plans to do an "early experience program" of selling the product in a small geographic area in the United States, having it available in pharmacies, he said.

Although the product has been shown to be safe, there is no evidence whatsoever that it should be taken by anyone who does not have mild or early stage Alzheimer's disease, Hughes said.

Early Alzheimer's patients drinking the combination of these nutrients is akin to pregnant women taking folic acid supplements, Wurtman said. It's not that they are deficient in these nutrients, but the addition of more of them carries benefits, he said.

Yian Gu, postdoctoral researcher in neurology at Columbia University Medical Center, who studies the relationship between diet and Alzheimer's, said the study looks promising if the claims of memory improvement hold up, but noted that further research should be done to confirm those results. There should also be comparisons with nutritional supplements currently available on the market, such as multivitamins and fish oil, Gu said.

There were also cognitive and memory tasks that the drink did not seem to improve, according to the study, and the researchers should look further into what other improvements can be seen besides the verbal recall finding, Gu said.

The study is published in the journal Alzheimer's & Dementia.

Not all the news on Alzheimer's treatments is positive. Patients in a phase III trial for tarenflurbil, a drug that showed promise in an earlier phase II trial, did not experience improvement in cognition or daily function compared with those who received a placebo, according to a recent study in the Journal of the American Medical Association.

Sunday, December 21, 2008

Alzheimer's test is a matter of memory, some argue

ChicagoTribune.com
December 21, 2008
There's no mammogram or PSA test for Alzheimer's disease. Yet an Alzheimer's group this month began a push for simple memory screenings in a bid to catch possible warning signs of dementia sooner.

Memory screening

Five-minute mini-tests, doable at a health fair, are hugely controversial. But the provocative new report from the Alzheimer's Foundation of America contends they're a valuable but overlooked tool. The government has begun reviewing whether there's enough science to back broader use of them.

A sample test

Tell someone....read the whole article

Read an important comment

For dementia information, click here

Do you want to read about dementia activities, click here
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info